Chlamydia pneumoniae and Helicobacter pylori IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study

Kalantarhormozi, Mohammadreza; Assadi, Majid; Vahdat, Katayoun; Asadipooya, Kamyar; Ostovar, Afshin; Katayoun, Raissi; Darabi, Hossein; Farrokhi, Shokrollah; Dobaradaran, Sina; Farrokhnia, Maryam; Nabipour, Iraj

doi:10.1007/s00774-015-0688-9

Cited by 15 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We read an article written by Kalantarhormozi et al [1] with interest. The authors prospectively evaluated antibodies against Helicobacter pylori in healthy postmenopausal women.…”

Section: Dear Editor-in-chiefmentioning

confidence: 98%

See 1 more Smart Citation

Association between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

were included in the meta-analysis. Four were crosssectional studies and one was a prospective cohort study. Studies were performed in Japan, South Korea, and Taiwan. All except Asaoka et al. [4] included only postmenopausal women. We performed a meta-analysis using a random-effects model. There is no significant association between H. pylori infection and osteoporosis with pooled OR = 1.49 (95 % CI 0.88-2.55, p = 0.14, I 2 = 52 %, P heterogeneity = 0.08).From this result, we demonstrated that H. pylori infection does not seem to be an important factor related to osteoporosis. This finding rejects the hypothesis that cytokines released from H. pylori infection lead to bone resorption and increase the risk of osteoporosis. Larger prospective studies that vary in ethnicity, age group and gender are required to determine the causal relationship between H. pylori and bone resorption. Further randomized controlled trials may be done to determine the role of H. pylori eradication in reducing the incidence of osteoporosis.

show abstract

“…We read an article written by Kalantarhormozi et al [1] with interest. The authors prospectively evaluated antibodies against Helicobacter pylori in healthy postmenopausal women.…”

Section: Dear Editor-in-chiefmentioning

confidence: 98%

“…From a total of 25 articles that underwent full-length review, five studies [1][2][3][4][5] involving 1,321 participants…”

Section: Dear Editor-in-chiefmentioning

confidence: 99%

Association between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Six studies included only women, mainly postmenopausal; in one report, the gender of the participants was not mentioned [ 95 ], in the rest of the studies there were 5801 males and 5522 females (M:F ratio 1:1.05). Of the 20 studies, 19 had a cross-sectional design, one analyzed a prospective cohort [ 96 ]. Nine studies were performed in Western countries (Italy, Turkey, Brazil (two reports from each) and Iran (three reports)) and eleven studies in Eastern countries/regions (Japan (five reports), Taiwan (four), South Korea (one) and China (one)).…”

Section: Hpi and Bone Statusmentioning

confidence: 99%

Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)

Fisher

Smith

2020

JCM

View full text Add to dashboard Cite

Osteoporosis (OP) and osteoporotic fractures (OFs) are common multifactorial and heterogenic disorders of increasing incidence. Helicobacter pylori (H.p.) colonizes the stomach approximately in half of the world’s population, causes gastroduodenal diseases and is prevalent in numerous extra-digestive diseases known to be associated with OP/OF. The studies regarding relationship between H.p. infection (HPI) and OP/OFs are inconsistent. The current review summarizes the relevant literature on the potential role of HPI in OP, falls and OFs and highlights the reasons for controversies in the publications. In the first section, after a brief overview of HPI biological features, we analyze the studies evaluating the association of HPI and bone status. The second part includes data on the prevalence of OP/OFs in HPI-induced gastroduodenal diseases (peptic ulcer, chronic/atrophic gastritis and cancer) and the effects of acid-suppressive drugs. In the next section, we discuss the possible contribution of HPI-associated extra-digestive diseases and medications to OP/OF, focusing on conditions affecting both bone homeostasis and predisposing to falls. In the last section, we describe clinical implications of accumulated data on HPI as a co-factor of OP/OF and present a feasible five-step algorithm for OP/OF risk assessment and management in regard to HPI, emphasizing the importance of an integrative (but differentiated) holistic approach. Increased awareness about the consequences of HPI linked to OP/OF can aid early detection and management. Further research on the HPI–OP/OF relationship is needed to close current knowledge gaps and improve clinical management of both OP/OF and HPI-related disorders.

show abstract

“…Whether H . pylori infection is a risk factor for osteoporosis remains controversial [ 20 – 23 ]. However, only a few studies have discussed the influence of H .…”

Section: Introductionmentioning

confidence: 99%

Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study

et al. 2016

View full text Add to dashboard Cite

PurposePrevious studies have reported conflicting results on the association between Helicobacter pylori infection and osteoporosis. A few studies have discussed the influence of H. pylori eradication therapy on bone mineral density.MethodsWe assessed the prevalence of osteoporosis among the H. pylori-infected population in Taiwan and the influence of early and late H. pylori eradication therapy on bone mineral density.ResultsUsing data from Taiwan's National Health Insurance Research Database, we identified 5,447 patients who received H. pylori eradication therapy from 2000 to 2010 and 21,788 controls, frequency-matched according to age, sex, and year of receiving H. pylori eradication therapy. Those who received H. pylori eradication therapy were divided into two groups based on the time interval between the diagnosis of a peptic ulcer and commencement of eradication therapy. The risk of developing osteoporosis was higher in the early H. pylori treatment cohort (hazard ratio [HR] = 1.52, 95% confidence interval [CI] = 1.23–1.89) and late H. pylori treatment cohort (HR = 1.69, 95% CI = 1.39–2.05), compared with the risk in the control cohort. When followed for less than 5 years, both the early and late cohorts had a higher risk of developing osteoporosis (HR = 1.69, 95% CI = 1.32–2.16 and HR = 1.72, 95% CI = 1.38–2.14). However, when the follow-up period was over 5 years, only the late eradication group exhibited a higher incidence of osteoporosis (HR = 1.62, 95% CI = 1.06–2.47).ConclusionThe development of osteoporosis is complex and multi-factorial. Via this population-based cohort study and adjustment of possible confounding variables, we found H. pylori infection may be associated with an increased risk of developing osteoporosis in Taiwan. Early eradication could reduce the influence of H. pylori infection on osteoporosis when the follow-up period is greater than 5 years. Further prospective studies are necessary to discover the connection of H. pylori and osteoporosis.

show abstract

Chlamydia pneumoniae and Helicobacter pylori IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study

Cited by 15 publications

References 19 publications

Association between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis

Association between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis

Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)

Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study

Contact Info

Product

Resources

About